Kiora Pharmaceuticals (NASDAQ:KPRX) Posts Quarterly Earnings Results, Misses Estimates By $0.40 EPS

Kiora Pharmaceuticals (NASDAQ:KPRX) released its quarterly earnings data on Tuesday. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.40), Zacks reports. The company had revenue of $0.75 million during the quarter, compared to analysts’ expectations of $0.75 million.

Kiora Pharmaceuticals Price Performance

NASDAQ KPRX opened at $3.04 on Wednesday. Kiora Pharmaceuticals has a one year low of $2.91 and a one year high of $6.48. The company’s 50-day simple moving average is $3.50 and its two-hundred day simple moving average is $3.49.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.